{"title":"用于预测生物人工瓣膜置换术后心血管事件的 R2-CHA2DS2-VASc 评分 - BPV-AF 登记的子分析。","authors":"Madoka Sano, Misa Takegami, Masashi Amano, Hidekazu Tanaka, Kenji Ando, Takeshi Kitai, Makoto Miyake, Tatsuhiko Komiya, Masaki Izumo, Hiroya Kawai, Kiyoyuki Eishi, Kiyoshi Yoshida, Takeshi Kimura, Ryuzo Nawada, Tomohiro Sakamoto, Yoshisato Shibata, Toshihiro Fukui, Kenji Minatoya, Kenichi Tsujita, Yasushi Sakata, Kumiko Sugio, Tadaaki Koyama, Tomoyuki Fujita, Kunihiro Nishimura, Chisato Izumi, Yutaka Furukawa","doi":"10.1253/circrep.CR-24-0033","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There are few studies evaluating the prognostic prediction method in atrial fibrillation (AF) patients after bioprosthetic valve (BPV) replacement. The R<sub>2</sub>-CHA<sub>2</sub>DS<sub>2</sub>-VASc score is increasingly used for the prediction of cardiovascular (CV) events in patients with AF, device implantation, and acute coronary syndrome. We aimed to evaluate the predictive value of the R<sub>2</sub>-CHA<sub>2</sub>DS<sub>2</sub>-VASc score for future CV events in AF patients after BPV replacement.</p><p><strong>Methods and results: </strong>The BPV-AF, an observational, multicenter, prospective registry, enrolled AF patients who underwent BPV replacement. The primary outcome measure was a composite of stroke, systemic embolism, CV events including heart failure requiring hospitalization, and cardiac death. A total of 766 patients was included in the analysis. The mean R<sub>2</sub>-CHA<sub>2</sub>DS<sub>2</sub>-VASc score was 5.7±1.8. Low (scores 0-1), moderate (scores 2-4), and high (scores 5-11) R<sub>2</sub>-CHA<sub>2</sub>DS<sub>2</sub>-VASc score groups consisted of 12 (1.6%), 178 (23.2%), and 576 (75.2%) patients, respectively. The median follow-up period was 491 (interquartile range 393-561) days. Kaplan-Meier analysis showed a higher incidence of the composite CV events in the high R<sub>2</sub>-CHA<sub>2</sub>DS<sub>2</sub>-VASc score group (log rank test; P<0.001). Multivariate Cox proportional hazards regression analysis revealed that the R<sub>2</sub>-CHA<sub>2</sub>DS<sub>2</sub>-VASc score as a continuous variable was an independent predictor of composite CV outcomes (hazard ratio 1.36; 95% confidence interval 1.18-1.55; P<0.001).</p><p><strong>Conclusions: </strong>The R<sub>2</sub>-CHA<sub>2</sub>DS<sub>2</sub>-VASc score is useful for CV risk stratification in AF patients after BPV replacement.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309778/pdf/","citationCount":"0","resultStr":"{\"title\":\"R<sub>2</sub>-CHA<sub>2</sub>DS<sub>2</sub>-VASc Score for Cardiovascular Event Prediction After Bioprosthetic Valve Replacement - Subanalysis From the BPV-AF Registry.\",\"authors\":\"Madoka Sano, Misa Takegami, Masashi Amano, Hidekazu Tanaka, Kenji Ando, Takeshi Kitai, Makoto Miyake, Tatsuhiko Komiya, Masaki Izumo, Hiroya Kawai, Kiyoyuki Eishi, Kiyoshi Yoshida, Takeshi Kimura, Ryuzo Nawada, Tomohiro Sakamoto, Yoshisato Shibata, Toshihiro Fukui, Kenji Minatoya, Kenichi Tsujita, Yasushi Sakata, Kumiko Sugio, Tadaaki Koyama, Tomoyuki Fujita, Kunihiro Nishimura, Chisato Izumi, Yutaka Furukawa\",\"doi\":\"10.1253/circrep.CR-24-0033\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>There are few studies evaluating the prognostic prediction method in atrial fibrillation (AF) patients after bioprosthetic valve (BPV) replacement. The R<sub>2</sub>-CHA<sub>2</sub>DS<sub>2</sub>-VASc score is increasingly used for the prediction of cardiovascular (CV) events in patients with AF, device implantation, and acute coronary syndrome. We aimed to evaluate the predictive value of the R<sub>2</sub>-CHA<sub>2</sub>DS<sub>2</sub>-VASc score for future CV events in AF patients after BPV replacement.</p><p><strong>Methods and results: </strong>The BPV-AF, an observational, multicenter, prospective registry, enrolled AF patients who underwent BPV replacement. The primary outcome measure was a composite of stroke, systemic embolism, CV events including heart failure requiring hospitalization, and cardiac death. A total of 766 patients was included in the analysis. The mean R<sub>2</sub>-CHA<sub>2</sub>DS<sub>2</sub>-VASc score was 5.7±1.8. Low (scores 0-1), moderate (scores 2-4), and high (scores 5-11) R<sub>2</sub>-CHA<sub>2</sub>DS<sub>2</sub>-VASc score groups consisted of 12 (1.6%), 178 (23.2%), and 576 (75.2%) patients, respectively. The median follow-up period was 491 (interquartile range 393-561) days. Kaplan-Meier analysis showed a higher incidence of the composite CV events in the high R<sub>2</sub>-CHA<sub>2</sub>DS<sub>2</sub>-VASc score group (log rank test; P<0.001). Multivariate Cox proportional hazards regression analysis revealed that the R<sub>2</sub>-CHA<sub>2</sub>DS<sub>2</sub>-VASc score as a continuous variable was an independent predictor of composite CV outcomes (hazard ratio 1.36; 95% confidence interval 1.18-1.55; P<0.001).</p><p><strong>Conclusions: </strong>The R<sub>2</sub>-CHA<sub>2</sub>DS<sub>2</sub>-VASc score is useful for CV risk stratification in AF patients after BPV replacement.</p>\",\"PeriodicalId\":94305,\"journal\":{\"name\":\"Circulation reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309778/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Circulation reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1253/circrep.CR-24-0033\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/9 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Circulation reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1253/circrep.CR-24-0033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/9 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
R2-CHA2DS2-VASc Score for Cardiovascular Event Prediction After Bioprosthetic Valve Replacement - Subanalysis From the BPV-AF Registry.
Background: There are few studies evaluating the prognostic prediction method in atrial fibrillation (AF) patients after bioprosthetic valve (BPV) replacement. The R2-CHA2DS2-VASc score is increasingly used for the prediction of cardiovascular (CV) events in patients with AF, device implantation, and acute coronary syndrome. We aimed to evaluate the predictive value of the R2-CHA2DS2-VASc score for future CV events in AF patients after BPV replacement.
Methods and results: The BPV-AF, an observational, multicenter, prospective registry, enrolled AF patients who underwent BPV replacement. The primary outcome measure was a composite of stroke, systemic embolism, CV events including heart failure requiring hospitalization, and cardiac death. A total of 766 patients was included in the analysis. The mean R2-CHA2DS2-VASc score was 5.7±1.8. Low (scores 0-1), moderate (scores 2-4), and high (scores 5-11) R2-CHA2DS2-VASc score groups consisted of 12 (1.6%), 178 (23.2%), and 576 (75.2%) patients, respectively. The median follow-up period was 491 (interquartile range 393-561) days. Kaplan-Meier analysis showed a higher incidence of the composite CV events in the high R2-CHA2DS2-VASc score group (log rank test; P<0.001). Multivariate Cox proportional hazards regression analysis revealed that the R2-CHA2DS2-VASc score as a continuous variable was an independent predictor of composite CV outcomes (hazard ratio 1.36; 95% confidence interval 1.18-1.55; P<0.001).
Conclusions: The R2-CHA2DS2-VASc score is useful for CV risk stratification in AF patients after BPV replacement.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
